Novel compound heterozygous mutations in OCA2 gene were identified in a Chinese family with oculocutaneous albinism.

BACKGROUND: Oculocutaneous albinism (OCA) is a group of rare autosomal recessive disorders characterized by clinical genetic heterogeneity. OCA type II (OMIM: 203200) is the most common subtype among African and African Americans, primarily caused by pathogenic variants in the OCA2 (HGNC ID: 8101) gene. In this study, we presented a Chinese family with OCA and reported two novel variants in the OCA2 gene. METHODS: Whole-exome sequencing (WES) was performed to identify pathogenic variants in the proband. The candidate variants were subsequently validated using Sanger sequencing and QPCR assay. Additionally, bioinformatics analyses were employed to predict the deleteriousness and conservation of the identified mutations. RESULTS: In the 16-year-old male proband, two novel compound heterozygous OCA2 variants, NM_000275.3: c.1640T>G (NP_000266.2: p.L547R) and an exons 10-19 deletion variant, were identified. Meanwhile, a reported heterozygous variant c.1441G>A/p.A481T (NM_000275.3, NP_000266.2) in the OCA2 gene was also found in the proband. Sanger sequencing confirmed that the two variants c.1441G>A/p.A481T and c.1640T>G/p.L547R were inherited from his father. Moreover, qPCR assay revealed that the exons 10-19 deletion was inherited from the mother, his sister also carried this variant. Fortunately, the variant was not detected in the amniotic fluid of the proband's sister. Multiple online bioinformatics tools predicted the variant c.1640T>G to be damaging, leading to the replacement of a highly conserved leucine with an arginine. The gross exon 10-19 deletion in the OCA2 gene resulted in a truncated, non-functional protein losing the 3-9 transmembrane α-helices domains. According to the American College of Medical Genetics and Genomics classification, these three variants in the OCA2 gene were evaluated as likely pathogenic. CONCLUSION: This study has identified two novel compound variants in the OCA2 gene and a previously reported variant in a Chinese family with OCA. By expanding the mutation spectrum of the OCA2 gene, our findings contribute to a better understanding of the genetic basis of OCA.

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation.

We present a case report of successful treatment with nirmatrelvir/ritonavir (Paxlvoid) for a severe aplastic anemia child with COVID-19, cytopenia, and mixed chimerism of donor hematopoietic cells at 3 months after allogeneic hematopoietic stem cell transplantation. After the 5-day entire course of treatment, the clinical symptoms were relieved, cycle threshold values of ORF1a/b and N genes increased from 22.60 and 22.15 to 34.52 and 33.84, respectively, and the peripheral blood counts gradually recovered without graft failure. Nirmatrelvir/ritonavir can effectively inhibit the replication of SARS-CoV-2 without any significant adverse effects.

Lewis Acidic PSbP Pincer Ligand in Pt-Catalyzed 1,6-Enyne Cycloisomerization: A Theoretical Study.

The progressively improved heterobimetallic antimony transition metal complex PSbP-Pt (I1) provides superior activity in catalyzed 1,6-enyne cycloisomerization. Our DFT calculations demonstrate that the noninnocent character of the antimony ligand enhances the self-activation of the catalyst precursor through a substrate-aided intramolecular chloride migration, which triggers subsequent reaction. Designed alternative redox noninnocent active species with strong electron-withdrawing groups also show promising catalytic ability due to an electron-deficient antimony ligand, which lowers the typical reaction barrier for the cycloisomerization of 1,6-enyne.

The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome.

Richter syndrome (RS) indicates the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma (mostly DLBCL). Richter syndrome is a rare complication with an aggressive clinical course, bearing an unfavorable prognosis. Currently, there is no effective treatment for it. As a novel cellular-based immune therapy, chimeric antigen receptor-modified T (CART) cells treatment is gradually used in treating hematological malignancies, especially in CD19+ B-cell malignancy. Therefore, CD19-directed chimeric antigen receptor-modified T cells (CART-19) treatment is promising to be used as a new method for RS patients. In our study, one RS patient expressing high level of CD19 molecule was enrolled in clinical trial; he has received a series of treatments but did not achieve a satisfactory therapeutic effect. The patient totally received 3.55 × 108 autologous CART-19 cells infusion. After CART-19 infusion, the mainly clinical side effect was repeated fever. The maximal duration period was 24 days and the highest temperature was 40.1°C. Pancytopenia and significantly serum cytokines level rise were observed, including IFN-γ, IL-6, and IL-10. Before discharge, the level of cytokines reduced to normal levels. In addition, we detected the serum biochemical indices as like K+ , Ca2+ , creatinine, and glutamic-pyruvic transaminase, all of these indices were normal. This showed that there was no tumor necrosis syndrome after treatment. The proportion of B cells in patient's peripheral blood decreased from 72% to 40.2% after infusion, co-occurring with reduction in lymph nodes and hematopoietic reconstitution. Based on the recent revolution in the therapeutic landscape for hematological malignancies including B-cell lymphomas, CART-CD19 cell therapy as a new therapeutic option for RS might be available in the coming years. It aims to reduce patient's tumor burden, prolong their survival time, and provide opportunities for other sequential therapy such as chemotherapy and bone marrow transplantation.

Effects of grain size and structural heterogeneity on the transport and retention of nano-TiO2 in saturated porous media.

Accurately predicting the fate and transport of nano-TiO2 in porous media is critical to assess its environmental impact. This study was designed to understand the effects of gain size and structural heterogeneity under different ionic strength (IS) on the fate and transport of nano-TiO2 in saturated porous media. In the columns packed homogenously with sand of different grain sizes (920, 550, 390, and 275µm), the transport of nano-TiO2 decreased when the IS increased from 0.1 to 1 or 10mM. For all the three IS conditions, the retention of the nano-TiO2 particles in the columns increased when the gain size decreased, and the mobility of the nano-TiO2 was the lowest in the sand at size of 275µm with recovery rates of 0.30% to 1.72%. The mass recovery rates of TiO2 in other homogeneous columns were higher and ranged from 0.37% to 59.9%. Structural heterogeneity created two flow domains for the retention and transport of nano-TiO2 particles in the saturated porous media. The fast-flow domain dominated the flow and transport processes of the nano-TiO2 in the heterogeneous columns under the tested conditions. As a result, the transport of nano-TiO2 in the heterogeneous porous media was faster and higher than that in the homogeneous columns under similar experimental conditions. Because of the dominance of the fast-flow domain, the recovery rates of the nano-TiO2 in the heterogeneous columns were similar and ranged from 59.8% to 66.9%. These results reflected the importance of preferential flow to the fate and transport of nano-TiO2 particle in porous media. Simulations from a two-domain model matched the experimental breakthrough curves very well.